Search Results - "den Broek, Wout van"

Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome by van den Broek, Wout W A, van Paassen, Jacqueline G, Gimbel, Marieke E, Deneer, Vera H M, ten Berg, Jurriën M, Vreman, Rick A

“…Abstract Objective The POPular AGE trial showed that clopidogrel significantly reduced bleeding risk compared with ticagrelor without any signs of an increase…”
Get full text

Global Longitudinal Strain is Incremental to Left Ventricular Ejection Fraction for the Prediction of Outcome in Optimally Treated Dilated Cardiomyopathy Patients by Raafs, Anne G, Boscutti, Andrea, Henkens, Michiel T H M, van den Broek, Wout W A, Verdonschot, Job A J, Weerts, Jerremy, Stolfo, Davide, Nuzzi, Vincenzo, Manca, Paolo, Hazebroek, Mark R, Knackstedt, Christian, Merlo, Marco, Heymans, Stephane R B, Sinagra, Gianfranco

“…Background Speckle tracking echocardiographic global longitudinal strain (GLS) predicts outcome in patients with new onset heart failure. Still, its…”
Get full text

Effects of CYP3A422 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study by Azzahhafi, Jaouad, Bergmeijer, Thomas O, van den Broek, Wout W A, Chan Pin Yin, Dean R P P, Rayhi, Senna, Peper, Joyce, Bor, Willem L, Claassens, Daniel M F, van Schaik, Ron H N, Ten Berg, Jurriën M

“…To determine the clinical efficacy, adverse events and side-effect dyspnea of and CYP3A5 expressor status in ticagrelor treated patients. Ticagrelor treated…”
Get full text

Is a genotype-guided therapy the optimal strategy to personalize anti-thrombotic management in patients with acute coronary syndrome? by van den Broek, Wout W A, Ten Berg, Jurriën M

Get full text

Another Step Toward CYP2C19 Genotype-Guided Therapy in Treatment With Dual Antiplatelet Therapy by ten Berg, Jurriën M., van den Broek, Wout W.A.

“…[Display omitted]…”
Get full text

CYP2C9 Polymorphisms and the Risk of Cardiovascular Events in Patients Treated with Clopidogrel: Combined Data from the POPular Genetics and POPular AGE Trials by van den Broek, Wout W. A., Mani, Nabil, Azzahhafi, Jaouad, ten Berg, Jurriën M.

“…Background The cytochrome P450 (CYP) 2C9 enzyme plays a role in the metabolization of clopidogrel. Carriage of a CYP2C9 loss-of-function (LoF) allele has been…”
Get full text

Real-World Implementation of a Genotype-Guided P2Y12 Inhibitor De-Escalation Strategy in Acute Coronary Syndrome Patients by Azzahhafi, Jaouad, van den Broek, Wout W.A., Chan Pin Yin, Dean R.P.P., van der Sangen, Niels M.R., Sivanesan, Shabiga, Bofarid, Salahodin, Peper, Joyce, Claassens, Daniel M.F., Janssen, Paul W.A., Harmsze, Ankie M., Walhout, Ronald J., Tjon Joe Gin, Melvyn, Nicastia, Deborah M., Langerveld, Jorina, Vlachojannis, Georgios J., van Bommel, Rutger J., Appelman, Yolande, van Schaik, Ron H.N., Henriques, José P.S., Kikkert, Wouter J., ten Berg, Jurriën M.

“…CYP2C19 genotype-guided de-escalation from ticagrelor or prasugrel to clopidogrel may optimize the balance between ischemic and bleeding risk in patients with…”
Get full text

Temporary omission of oral anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention: rationale and design of the WOEST-3 randomised trial by Verburg, Ashley, Bor, Wilbert L, Küçük, I Tarik, Henriques, José P S, Vink, Maarten A, Ruifrok, Willem-Peter T, Plomp, Jacobus, Heestermans, Ton A C M, Schotborgh, Carl E, Vlaar, Pieter J, Magro, Michael, Rikken, Sem A O F, van den Broek, Wout W A, van Mieghem, Carlos A G, Cornelis, Kristoff, Rosseel, Liesbeth, Dujardin, Karl S, Vandeloo, Bert, Vandendriessche, Tom, Ferdinande, Bert, van 't Hof, Arnoud W J, Tijssen, Jan G P, Limbruno, Ugo, De Caterina, Raffaele, Rubboli, Andrea, Angiolillo, Dominick J, Adriaenssens, Tom, Dewilde, Willem, Ten Berg, Jurrien M

“…The optimal antithrombotic management of atrial fibrillation (AF) patients who require oral anticoagulation (OAC) undergoing percutaneous coronary intervention…”
Get more information

Treatment of elderly patients with non-ST-elevation myocardial infarction: the nationwide POPular age registry by Gimbel, Marieke E., Chan Pin Yin, Dean R. P. P., van den Broek, Wout W. A., Hermanides, Renicus S., Kauer, Floris, Tavenier, Annerieke H., Schellings, Dirk, Brinckman, Stijn L., The, Salem H. K., Stoel, Martin G., Heestermans, Ton A. C. M., Rasoul, Saman, Emans, Mireille E., van de Wetering, Machiel, van Bergen, Paul F. M. M., Walhout, Ronald, Nicastia, Debby, Aksoy, Ismail, van ’t Hof, Arnoud, Knaapen, Paul, Botman, Cees-Joost, Liem, Anho, de Nooijer, Cornelis, Peper, Joyce, Kelder, Johannes C., ten Berg, Jurriën M.

“…Objective We describe the current treatment of elderly patients with non-ST-elevation myocardial infarction (NSTEMI) enrolled in a national registry. Methods…”
Get full text

The puzzle of antiplatelet therapy in ACS: ticagrelor monotherapy is another missing piece by van den Broek, Wout W A, ten Berg, Jurriën M

“…Graphical Abstract Graphical Abstract The optimal antithrombotic therapy in patients after an acute coronary syndrome consists of balancing each patient’s…”
Get full text

Conservative versus Invasive Strategy in Elderly Patients with Non-ST-Elevation Myocardial Infarction: Insights from the International POPular Age Registry by van den Broek, Wout W. A., Gimbel, Marieke E., Chan Pin Yin, Dean R. P. P., Azzahhafi, Jaouad, Hermanides, Renicus S., Runnett, Craig, Storey, Robert F., Austin, David, Oemrawsingh, Rohit, Cooke, Justin, Galasko, Gavin, Walhout, Ronald J., Schellings, Dirk A. A. M., Brinckman, Stijn L., The, Hong Kie, Stoel, Martin G., Heestermans, Antonius A. C. M., Nicastia, Debby, Emans, Mireille E., van ’t Hof, Arnoud W. J., Alber, Hannes, Gerber, Robert, van Bergen, Paul F. M. M., Aksoy, Ismail, Nasser, Abdul, Knaapen, Paul, Botman, Cees-Joost, Liem, Anho, Kelder, Johannes C., ten Berg, Jurriën M.

“…This registry assessed the impact of conservative and invasive strategies on major adverse clinical events (MACE) in elderly patients with non-ST-elevation…”
Get full text

The Clinical Implementation of CYP2C19 Genotyping in Patients with an Acute Coronary Syndrome: Insights From the FORCE-ACS Registry by Azzahhafi, Jaouad, Broek, Wout W. A. van den, Chan Pin Yin, Dean R. P. P., Harmsze, Ankie M., van Schaik, Ron H. N., ten Berg, Jurriën M.

“…Background Guidelines recommend prasugrel or ticagrelor for acute coronary syndrome (ACS) patients. However, these P2Y12 inhibitors increase bleeding risk…”
Get full text

Genotype-Guided Antiplatelet Therapy: JACC Review Topic of the Week by van den Broek, Wout W A, Ingraham, Brenden S, Pereira, Naveen L, Lee, Craig R, Cavallari, Larisa H, Swen, Jesse J, Angiolillo, Dominick J, Ten Berg, Jurriën M

“…The clinical efficacy and safety of antiplatelet agents vary among patients. Consequently, some patients are at increased risk of recurrent ischemic events…”
Get full text

Is there a benefit for CYP2C19 genotype-guided antiplatelet treatment in elderly acute coronary syndrome patients? by van den Broek, Wout Wa, Ten Berg, Jurriën M

Get full text

P2Y12 Inhibition in Patients Requiring Oral Anticoagulation after Percutaneous Coronary Intervention: The SWAP-AC–2 Study by Ortega-Paz, Luis, Bor, Wilbert, Franchi, Francesco, van de Broek, Wout W.A., Rollini, Fabiana, Giordano, Salvatore, Galli, Mattia, Been, Latonya, Ghanem, Ghussan, Shalhoub, Awss, Garabedian, Haroutioun, Al Saleh, Tala, Uzunoglu, Ekin, Zhou, Xuan, Rivas, Andrea, Pineda, Andres M., Suryadevara, Siva, Soffer, Daniel, Mahowald, Madeline K., Choi, Calvin Y., Zenni, Martin M., Phoenix, Fladia, Ajjan, Ramzi A., ten Berg, Jurrien M., Angiolillo, Dominick J.

“…Among patients treated with a novel oral anticoagulant (NOAC) undergoing percutaneous coronary intervention (PCI), combination therapy with clopidogrel (ie,…”
Get full text

The Sixth European Society of Pharmacogenomics and Personalised Therapy Congress (Belgrade, 8–9 November 2022) by van Schaik, Ron Hn, Manolopoulos, Vangelis G, Daly, Ann K, Niemi, Mikko, Zukic, Branka, Patrinos, George P, Primorac, Dragan, Swen, Jesse J, Ingelman-Sundberg, Magnus, Morris, Tiffany, Molden, Espen, Müller, Daniel, Pavlovic, Sonja, Russmann, Stefan, Ansari, Marc, Henricks, Linda M, den Broek, Wout van, Florindi, Francesco, Bozina, Nada, Akin, Demet, Christrup, Lona, Llerena, Adrian, Sipeky, Cilla, Stankovic, Sanja

“…On 8–9 November 2022, the European Society of Pharmacogenomics and Personalised Therapy organized its sixth biennial congress, in Belgrade, Serbia (congress…”
Get full text

TCT-381 The Clinical implementation of CYP2C19 Genotyping in Patients With an Acute Coronary Syndrome: Insights From the FORCE-ACS Registry by Azzahhafi, Jaouad, van den Broek, Wout, Chan Pin Yin, Dean, Van Schaik, Ron, Berg, Jurrien Ten

Get full text

TCT-228 Treatment Modifications in Ticagrelor-Treated Patients: Insights From the FORCE-ACS Registry by van der Sangen, Niels, Azzahhafi, Jaouad, Chan Pin Yin, Dean, Zaaijer, Lucas, van den Broek, Wout, Henriques, Jose, Kikkert, Wouter, Berg, Jurrien Ten

Get full text

Genotype-Guided Antiplatelet Therapy by van den Broek, Wout W.A., Ingraham, Brenden S., Pereira, Naveen L., Lee, Craig R., Cavallari, Larisa H., Swen, Jesse J., Angiolillo, Dominick J., ten Berg, Jurriën M.

“…The clinical efficacy and safety of antiplatelet agents vary among patients. Consequently, some patients are at increased risk of recurrent ischemic events…”
Get full text

Abstract 4144803: Association of ENTPD-1 SNP genotype on inflammatory cell phenotype and ST-elevation myocardial infarction cardiovascular outcomes: a post-hoc analysis of the POPular Genetics by van den Broek, Wout, Watson, Samuel, Bergmeijer, Thomas, azzahhafi, jaouad, Magorien, Raymond, Mazzaferri, Ernest, Lilly, Scott, Attar, Talal, Boudoulas, Konstantinos, Madiai, Francesca, Covarrubias, Roman, ten berg, jurrien, Gumina, Richard

“…Abstract only Background: ST elevation myocardial infarction (STEMI) patients are at increased risk for secondary cardiovascular events. Modulation of…”
Get full text